These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23529209)

  • 1. Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.
    Eckermann S; Willan AR
    Pharmacoeconomics; 2013 May; 31(5):393-401. PubMed ID: 23529209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemics.
    Eckermann S
    Front Public Health; 2022; 10():1085319. PubMed ID: 36582386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Globally optimal trial design for local decision making.
    Eckermann S; Willan AR
    Health Econ; 2009 Feb; 18(2):203-16. PubMed ID: 18435429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of value of information: best informing research design and prioritization using current methods.
    Eckermann S; Karnon J; Willan AR
    Pharmacoeconomics; 2010; 28(9):699-709. PubMed ID: 20629473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
    Edlin R; Hall P; Wallner K; McCabe C
    Value Health; 2014 Jun; 17(4):438-44. PubMed ID: 24969005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lay public's understanding of equipoise and randomisation in randomised controlled trials.
    Robinson EJ; Kerr CE; Stevens AJ; Lilford RJ; Braunholtz DA; Edwards SJ; Beck SR; Rowley MG
    Health Technol Assess; 2005 Mar; 9(8):1-192, iii-iv. PubMed ID: 15763039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The option value of delay in health technology assessment.
    Eckermann S; Willan AR
    Med Decis Making; 2008; 28(3):300-5. PubMed ID: 18480035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.
    Walker S; Sculpher M; Claxton K; Palmer S
    Value Health; 2012 May; 15(3):570-9. PubMed ID: 22583469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of interventions for informed consent for randomised controlled trials (ELICIT): protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
    Gillies K; Entwistle V; Treweek SP; Fraser C; Williamson PR; Campbell MK
    Trials; 2015 Oct; 16():484. PubMed ID: 26507504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who will consent to emergency treatment trials for subarachnoid hemorrhage?
    Del Giudice A; Plaum J; Maloney E; Kasner SE; Le Roux PD; Baren JM
    Acad Emerg Med; 2009 Apr; 16(4):309-15. PubMed ID: 19298620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.
    Pearce M; Hee SW; Madan J; Posch M; Day S; Miller F; Zohar S; Stallard N
    BMC Med Res Methodol; 2018 Feb; 18(1):20. PubMed ID: 29422021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time and expected value of sample information wait for no patient.
    Eckermann S; Willan AR
    Value Health; 2008; 11(3):522-6. PubMed ID: 18179665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.